Evaluating the Platinum-free Interval in Recurrent Endometrial Cancer: Should it Affect Decision to Retreat with Platinum-based Chemotherapy Versus Combination Lenvatinib and Pembrolizumab?

Grant

Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Rebecca Arend M.D.   Principal Investigator